SCHEMBL6285928

SCHEMBL6285928

COc1ccc(-c2cc3ccncc3[nH]2)cc1NC(=O)N(S)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPK1 P28482 1/20 0.39
ICOSLG O75144 2/20 0.39
ICOS Q9Y6W8 2/20 0.39
POLB P06746 1/20 0.38
CHUK O15111 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALOX15 P16050 1/20 0.37
ACLY P53396 2/20 0.36
F3 P13726 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GSK3B P49841 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
TP53 P04637 1/20 0.35
NR3C1 P04150 1/20 0.35
NR3C2 P08235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286958 0.93 F3 (0.43) KMT2AMEN1MAPK1ICOSLGICOS
SCHEMBL6286360 0.90 ACLY (0.38) KMT2AMEN1ALOX15ACLYNPSR1
SCHEMBL6496749 0.87 ALOX15 (0.48) KMT2AMEN1POLBSMN1; SMN2TDP1
SCHEMBL6288131 0.85 IRAK4 (0.40) KMT2AMEN1MAPK1ICOSLGICOS
SCHEMBL6286030 0.85 ALDH1A1 (0.53) KMT2AMEN1SMN1; SMN2TDP1NPSR1
SCHEMBL6288150 0.85 ACLY (0.37) KMT2AMEN1MAPK1POLBALOX15
SCHEMBL6279221 0.85 RIPK1 (0.52) MAPK1
SCHEMBL6288186 0.84 IRAK4 (0.38) KMT2AMEN1MAPK1POLBACLY
SCHEMBL6504814 0.84 ACLY (0.38) KMT2AMEN1ALOX15ACLYNPSR1
SCHEMBL6286006 0.83 CCNB2 (0.44) KMT2AMEN1MAPK1POLBACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US claimed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B KMT2A 4200/4885MEN1 3508/4885MAPK1 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.